MS Research Update — April 22, 2026
Updated Thesis
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7% ROE, the stock trades significantly above its fair value estimate of $131.49, with a current price of $189.30 representing 30.5% downside to fair value.
The investment grade as of this refresh is C — average business quality. High-tier business, mid-tier valuation with 30.5% downside to $131.49 fair value
Key Metrics at a Glance
- Revenue growth: +18.8% year over year
- Net margin: 15.1%
- Forward P/E: 16.4x
- Fair value upside: -30.5% to our estimate of $131
Current price: $189.30
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Morgan Stanley remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MS research →](/stocks/MS)